Collagenase injections for Dupuytren's disease: prospective cohort study assessing 2-year treatment effect durability

BMJ Open. 2017 Mar 15;7(3):e012943. doi: 10.1136/bmjopen-2016-012943.

Abstract

Objectives: To assess 2-year durability of joint contracture correction following collagenase injections for Dupuytren's disease.

Design: Prospective cohort study.

Setting: Orthopaedic Department in Sweden.

Participants: Patients with palpable Dupuytren's cord and active extension deficit (AED) ≥30° in the metacarpophalangeal (MCP) and/or proximal interphalangeal (PIP) joint. A surgeon injected 0.80 mg collagenase into multiple cord parts and performed finger manipulation under local anaesthesia after 24-48 hours. A hand therapist measured joint contracture before and 5 weeks after injection in all treated patients. Of 57 consecutive patients (59 hands), 48 patients (50 hands) were examined by a hand therapist 24-35 months (mean 26) after injection. Five of the patients had received a second injection in the same finger within 6 months of the first injection.

Outcome measures: Primary outcome was proportion of treated joints with ≥20° worsening in AED from 5 weeks to 2 years.

Results: Between the 5-week and the 2-year measurements, AED had worsened by ≥20° in seven MCP and seven PIP joints (28% of the treated hands; all had received a single injection). Mean AED for the MCP joints was 54° before injection, 6° at 5 weeks and 9° at 2 years and for the PIP joints 30°, 13° and 16°, respectively. For joints with ≥10° contracture at baseline, mean (95 % CI) baseline to 2 years AED improvement was for MCP 49° (41-54) and for PIP 25° (17-32). No treatment-related adverse events were observed at the 2-year follow-up evaluation.

Conclusions: Two years after collagenase injections for Dupuytren's disease, improvement was maintained in 72% of the treated hands. Complete contracture correction was seen in more than 80% of the MCP but in less than half of the PIP joints.

Keywords: Collagenase; Dupuytren.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Collagenases / administration & dosage
  • Collagenases / therapeutic use*
  • Dupuytren Contracture / drug therapy*
  • Female
  • Finger Joint*
  • Hand / pathology*
  • Humans
  • Injections
  • Male
  • Metacarpophalangeal Joint*
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Prospective Studies
  • Treatment Outcome

Substances

  • Collagenases